News

WATERTOWN, Mass., May 25, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (SELB) – Get Report, a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021.

The presentation on Tuesday, June 1 at 9:30 a.m. ET will be available through the Jefferies conference portal and an archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.Selecta Biosciences Inc. (SELB) – Get Report is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit  www.selectabio.com.

For Investors:Bruce MackleLifeSci Advisors, LLC+1-929-469-3859 bmackle@lifesciadvisors.com

For Media: Meredith Sosulski, Ph.D.LifeSci Communications, LLC+1-929-469-3851 msosulski@lifescicomms.com